Vonoprazan fumarate is a patented anticoagulant containing the antithrombin and fumarate elements. The primary component of the medicine is pyridinium. It has been proven to improve blood flow and reduce gastrointestinal permeability.
Due to these properties, it is used in the treatment of gastric ulcer and other gastrointestinal disorders. It has been shown to be effective in preventing the development of blood clots, reducing pain and improving survival rate for individuals with severe ulcerative colitis.
Ulcerative colitis is an inflammatory bowel disease. It is characterized by ulcers in the large intestine (colon). Symptoms include abdominal pain, nausea, and fever. This condition is not life threatening, but it can cause complications such as perforation, bleeding, or ulceration. It is important to take anticoagulant medicines such as fumarate before, during, and after the development of ulcerative colitis symptoms.
1260141-27-2 is formulated to increase the permeability of the small and large intestine and to improve the gastric acid secretion and motility of the small and large intestine. Both its active ingredient and its non-active ingredient are known to increase the permeability of the intestines. This results to better absorption of nutrients and substances in the food consumed.
The mechanism of action of this medicine involves the participation of P-cab (p-chloroacetic acid) and potassium-competitive acid blocker. P-cab and P-fluorophenyl are naturally occurring compounds found in grape skins. It is believed that these two ingredients work synergistically to enhance acid-related diseases and gastrointestinal disorders. The acid-related diseases include irritable bowel syndrome and Crohn’s disease. Its effects on ulcerative colitis symptoms are yet to be proven.
Clinical studies conducted by Chinese researchers showed that the combination of fumarate and potassium-based acid blocker helped in the treatment of patients with irritable bowel syndrome and Crohn’s disease. Patients treated with this combination had a significant improvement in their diarrhea and their gastric acid secretion improved.
These studies also revealed that patients taking this combination had a significant reduction in the occurrence of osteoarthritis. Furthermore, it is believed that P-cab and fumarate help protect the mucous lining in the stomach from ulcerations and thus can prevent the occurrence of irritable bowel syndrome, Crohn’s disease and ulcerative colitis.
Further clinical studies are underway to determine whether fumarate has the same effect on ulcerative colitis.
Clinical studies have also revealed that patients with ulcerative colitis who used the combination of P-cab and fumarate had a significant improvement in the control of their ulcer. Compared to those who did not use this combination, those who took this combination had a significant improvement in their disease.
However, there are no clinical trials presently underway to assess the effect of P-cab and fumarate on ulcerative colitis. Because of the promising results of these studies, this treatment is recommended for the control of reflux and heartburn in patients with gastro-esophageal reflux disease. However, we need to wait until all the data are out in order to draw conclusions about its efficacy in the treatment of this condition. If you want to know more information, you can visit here.